Latest Forum Topics /
Riverstone
Last:0.865
+0.005
|
 Post Reply
|
|
RIVERSTONE HOLDINGS LIMITED
|
|||||
|
Alson18
Senior |
07-Dec-2020 10:40
|
||||
|
x 0
x 0 Alert Admin |
Buy and Hold safe | ||||
| Useful To Me Not Useful To Me | |||||
|
Peter88
Senior |
07-Dec-2020 10:35
|
||||
|
x 0
x 0 Alert Admin |
Bought somemore at 1.20 . | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
SGPhantom
Master |
07-Dec-2020 10:09
|
||||
|
x 0
x 0 Alert Admin |
Another mini Pump & Dump day? | ||||
| Useful To Me Not Useful To Me | |||||
|
Peter88
Senior |
07-Dec-2020 09:24
|
||||
|
x 0
x 0 Alert Admin |
Those who are scared of vaccine news are seling cheaply , when they finish selling , we wont see this prcie again. | ||||
| Useful To Me Not Useful To Me | |||||
|
Joelton
Supreme |
07-Dec-2020 09:21
|
||||
|
x 0
x 0 Alert Admin |
Riverstone Holdings
On Dec 1, the Employees Provident Fund Board of Malaysia (EPF) increased its substantial shareholding of Riverstone Holdings to above the 7.00 per cent threshold.
This followed on from a filing on Oct 26 that reported the EPF increased its substantial shareholder above the 6.00 per cent threshold, after the EPF became a substantial shareholder of Riverstone Holdings on Sept 17.
In crossing the 7.00 per cent threshold, the one million shares, bought at a price of S$1.32 per share, took EPF' s total interest in Riverstone Holdings to 7.02 per cent.
Between Dec 1 and 2, Riverstone Holdings executive chairman and CEO Wong Teek Son acquired 100,000 shares of the company for a consideration of S$132,000.
At an average price of S$1.32 per share, the acquisitions increased his total interest in Riverstone Holdings from 51.13 per cent to 51.14 per cent.
He is the founder of Riverstone and was appointed to the board as executive chairman in August 2005.
Mr Wong' s executive responsibilities include developing business strategies as well as overseeing the group' s operations.
His preceding acquisitions were made between Nov 20 and 24, with 200,000 shares acquired at S$1.35 per share.
Riverstone Holdings has been among Singapore' s most traded 40 stocks in the 2020 year to date with average daily turnover close to S$10 million a day.
The company noted back on Nov 9 that phase 6 of the group' s expansion plans is on track to raise total production capacity by 1.5 billion pieces to 10.5 billion pieces of gloves annually by the end of 2020.
For phase 6, the group noted that it had commissioned five production lines that are currently in operation, with the remaining two production lines to be progressively commissioned over the next two months.
Furthermore, due to the strong demand for both healthcare and cleanroom gloves, the group' s current order book has been filled to the first half of 2021.
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Sgvale
Supreme |
07-Dec-2020 09:19
|
||||
|
x 0
x 0 Alert Admin |
Will it shoot up later? Big bosses increase buying now
|
||||
| Useful To Me Not Useful To Me | |||||
|
Peter88
Senior |
07-Dec-2020 08:51
|
||||
|
x 0
x 0 Alert Admin |
Good opportunity to accumulate when there is a continued prcie weakess. | ||||
| Useful To Me Not Useful To Me | |||||
|
Sgvale
Supreme |
07-Dec-2020 08:27
|
||||
|
x 0
x 0 Alert Admin |
Increase stake plus Boss share buyback . POWER!
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Checkerman
Master |
07-Dec-2020 08:14
|
||||
|
x 0
x 0 Alert Admin |
Today will fall again | ||||
| Useful To Me Not Useful To Me | |||||
|
Longtermer
Elite |
07-Dec-2020 07:56
Yells: "A disciplined investor is a wealthy investor" |
||||
|
x 0
x 0 Alert Admin |
Malaysia' s EPF increases Riverstone stake to 7% MON, DEC 07, 2020 - BT Riverstone Holdings On Dec 1, the Employees Provident Fund Board of Malaysia (EPF) increased its substantial shareholding of Riverstone Holdings to above the 7.00 per cent threshold. This followed on from a filing on Oct 26 that reported the EPF increased its substantial shareholder above the 6.00 per cent threshold, after the EPF became a substantial shareholder of Riverstone Holdings on Sept 17. In crossing the 7.00 per cent threshold, the one million shares, bought at a price of S$1.32 per share, took EPF' s total interest in Riverstone Holdings to 7.02 per cent. Between Dec 1 and 2, Riverstone Holdings executive chairman and CEO Wong Teek Son acquired 100,000 shares of the company for a consideration of S$132,000. At an average price of S$1.32 per share, the acquisitions increased his total interest in Riverstone Holdings from 51.13 per cent to 51.14 per cent. He is the founder of Riverstone and was appointed to the board as executive chairman in August 2005. Mr Wong' s executive responsibilities include developing business strategies as well as overseeing the group' s operations. His preceding acquisitions were made between Nov 20 and 24, with 200,000 shares acquired at S$1.35 per share. Riverstone Holdings has been among Singapore' s most traded 40 stocks in the 2020 year to date with average daily turnover close to S$10 million a day. The company noted back on Nov 9 that phase 6 of the group' s expansion plans is on track to raise total production capacity by 1.5 billion pieces to 10.5 billion pieces of gloves annually by the end of 2020. For phase 6, the group noted that it had commissioned five production lines that are currently in operation, with the remaining two production lines to be progressively commissioned over the next two months. Furthermore, due to the strong demand for both healthcare and cleanroom gloves, the group' s current order book has been filled to the first half of 2021. |
||||
| Useful To Me Not Useful To Me | |||||
|
Longtermer
Elite |
07-Dec-2020 07:43
Yells: "A disciplined investor is a wealthy investor" |
||||
|
x 0
x 0 Alert Admin |
Covid-19 vaccines: What is happening right now with their progress 3 Dec , SINGAPORE It has been close to a year since Covid-19 was first reported and the number of cases across the globe continues to rise. Scientists have been working round the clock to develop vaccines to put an end to the pandemic that has claimed more than 1.48 million lives worldwide &mdash a monumental task that typically takes years to complete.The New York Times reported in late November that researchers are testing 57 vaccines in clinical trials on humans, and at least 87 preclinical vaccines are under active investigation in animals.So far, two companies have made promising progress. WHICH VACCINES ARE AT FRONT OF THE RACE Reuters reported that both Moderna and Pfizer-BioNTech are in a tight race to launch their Covid-19 vaccines in Europe after both applied for emergency European Union (EU) approval on Tuesday (Dec 1). Drug maker Pfizer from the United States is collaborating with German development partner BioNTech. Moderna is an American biotech firm. Both have reported preliminary findings of more than 90 per cent effectiveness in trials of their vaccines &mdash an unexpectedly high rate. On Wednesday, Britain announced that it had approved the Pfizer- BioNTech Covid-19 vaccine for use and said that it will be rolled out from early next week. In Singapore, Moderna said on Monday that it is &ldquo forging ahead&rdquo with the rolling review process for its Covid-19 vaccine candidate with the Health Sciences Authority (HSA). HSA did not reply to TODAY&rsquo s questions about the latest development from Pfizer- BioNTech, but it did say that it has been in discussions with Moderna on the &ldquo rolling submission plan&rdquo for its Covid-19 vaccine. Moderna has started submitting initial data and will continue to roll in data as soon as it becomes available as agreed with (us),&rdquo HSA said. &ldquo To ensure expeditious review, (we have) already started evaluating the available data submitted by Moderna. For its part, Singapore intends to secure a portfolio of Covid-19 vaccines, Health Minister Gan Kim Yong said last month. The Ministry of Health said then that a broad and diversified portfolio of vaccines would improve Singapore&rsquo s chances of securing a suitable vaccine against the coronavirus.It added that while Singapore has expanded its vaccine portfolio with a number of pharmaceutical firms that use different technologies, and their vaccines are in different phases of clinical trials, not all will succeed or be suitable, safe and efficacious for all segments of the population. WHAT HSA HAS BEEN DOING The authorities here have not yet made public a list of the firms that are in talks to provide vaccines to Singapore. In the meantime, HSA said that it is allowing companies to submit real-time data from ongoing studies while it conducts a regulatory review at the same time. This is to try to speed up the approval process, while ensuring that there is enough scientific evidence to support the quality, safety and efficacy of the product. Even though it is possible to reduce the regulatory turnaround time, HSA stressed that there must be no significant adverse events, so relevant studies to support safety and efficacy are to be submitted before the vaccine is ready to be used publicly. PROGRESS OF OTHER VACCINES British bio-pharmaceutical firm AstraZeneca said on Nov 26 that more research was needed on its Covid-19 vaccine after questions emerged over the protection it offers.The announcement came days after AstraZeneca and its partner, the University of Oxford, said that they were seeking regulatory approval for the vaccine, which had shown an average 70 per cent effectiveness. That rate jumped to 90 per cent &mdash similar to that in rival vaccines from Pfizer-BioNTech and Moderna &mdash when an initial half-dose then a full dose was given to a sub-group of trial participants in error. Interim late-stage trial results for Russia&rsquo s Sputnik V vaccine, published on Nov 11, showed a 92 per cent effectiveness. Russian president Vladimir Putin ordered local authorities on Wednesday to begin mass voluntary vaccinations against Covid-19 next week, after the country recorded 589 new daily deaths from the coronavirus. To do this, Mr Putin said Russia will have to produce two million vaccine doses within the next few days. China has at least three companies, including China National Biotec Group, Can Sino Biologics and Sinovac Biotech that have signed deals with various countries to provide vaccines in bulk when ready. The Chinese drug makers had to look abroad for places to conduct late-stage trials for their vaccines because they have largely eliminated the coronavirus within their borders, CNN reported. In exchange, many of the host countries, such as Mexico and Brazil, have been promised early access to the successful vaccines, and even the technology to manufacture them for some. CHALLENGES AHEAD However, even when the vaccines are ready to be rolled out, there will be some logistical matters that need to be addressed. Chief among them would be preserving the vaccine in the tropical heat for countries within Southeast Asia. For instance, experts told Reuters that the genetic material used for making Pfizer-BioNTech&rsquo s vaccine needs to be at temperatures of -70° C or below.Such requirements pose a particularly daunting challenge for countries in Asia, as well as in places such as Africa and Latin America, where intense heat is often compounded by poor infrastructure that will make it difficult to keep the " cold chain" intact during deliveries to rural areas and islands. To help mitigate this problem here, Singapore Airlines has formed a Covid-19 Vaccine Taskforce to handle vaccine carriage.It has since been awarded with the International Air Transport Association&rsquo s Center of Excellence for Independent Validators in Pharmaceutical Logistics (CEIV Pharma) certification to recognise that it has the capacity to ensure the safe transportation of pharmaceutical goods. WHY FASTER IS NOT ALWAYS BETTER Although it may be tempting to think that the end of the pandemic might be in sight, particularly with news that vaccines are close to being available, several health experts have cautioned against hasty approvals. In response to Britain&rsquo s approval of Pfizer- BioNTech, the European Medicines Agency, which is in charge of approving Covid-19 vaccines for the EU, said that a longer procedure to approve vaccines is more appropriate because it would be based on more evidence and checks. Assistant Professor Hannah Clapham, who researches infectious disease at the Saw Swee Hock School of Public Health in the National University of Singapore, made a similar warning in a commentary for the East Asia Forum in October. She said that typically, trials take three to five years to complete with a vaccine candidate that is already developed. For Covid-19, developments have been sped up to a matter of months. The trouble comes when vaccines are rushed through at the expense of extensive testing, which could produce safety issues that are yet to be determined. Furthermore, Asst Prof Clapham said that individuals in the final stages of a trial are usually closely monitored and there is no guarantee of this happening in a real-world setting once vaccines are in use. Citing an AstraZeneca vaccine trial in the United Kingdom as an example, she said the trial had to be stopped and restarted after a participant had a suspected adverse reaction. If the vaccines do not work as promised, she said this could lead to individuals feeling reluctant to get vaccinated. Vaccine hesitancy is widespread and the risk of increasing vaccine hesitancy by rolling out a vaccine without adequate testing is not a risk worth taking, she wrote |
||||
| Useful To Me Not Useful To Me | |||||
|
SGPhantom
Master |
07-Dec-2020 01:29
|
||||
|
x 0
x 0 Alert Admin |
You still have not replied
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Mikasan
Member |
06-Dec-2020 23:55
|
||||
|
x 0
x 0 Alert Admin |
I' d go for this company, of all glove companies, as it is now fiscally sound.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Peter88
Senior |
06-Dec-2020 23:55
|
||||
|
x 0
x 0 Alert Admin |
Business activities of Riverstone HoldingsMalaysia-based Riverstone is a global market leader in the manufacturing of nitrile and clean room gloves as well as premium nitrile gloves used in the healthcare industry. The company&rsquo s proprietary &ldquo RS Riverstone Resources&rdquo brand is the preferred cleanroom gloves used in high-tech manufacturing industries. Its customers are global leaders in the semiconductor, pharmaceutical and healthcare industries, just to name a few. As at 31 December 2019, the company has an annual production capacity of 9.0 billion gloves and employs more than 3,000 people throughout its 6 manufacturing facilities - 4 in Malaysia, 1 in Thailand and 1 in China. Following its recent 1H 2020 results, Investor-One held an online webinar with Executive Chairman and CEO Mr. Wong Teek Son to understand more about the business with and see what is in store for retail investors. Here are snippets of the webinar highlights (edited for more context): 1. What are some notable developments that Riverstone&rsquo s shareholders can look forward to?Mr. Wong: Riverstone&rsquo s current capacity is 10 billion pieces a month, and it is going to commission 1 double line until November 2020. By the end of 2020, our capacity will be around 10.5 billion pieces. We have also spent around $80 million to build another factory which will be completed end 2021. Once completed, the capacity will increase by another 1.5 billion pieces. We will continue to have another factory by 2022 and 2023, and the capacity would grow to around 15 billion pieces per month. 2. There are several listed glove maker peers in the same industry. Can you share some of your competitive strengths and how do you maintain this edge over your peers?Mr. Wong: Riverstone is different from its peers because it has 2 main business segments &ndash healthcare and cleanroom gloves. For the cleanroom gloves, Riverstone is a clear leader supported by high barriers of entry due to the intricate production process. The company also takes part in the whole process from manufacturing to delivery, resulting in much higher profit margins for this segment. An important fact is that even though cleanroom gloves only occupy 15% of Riverstone&rsquo s total capacity, the segment constitutes to 50% of their gross profit margins. In addition, Riverstone is a technology-driven company - we are the first nitrile gloves manufacturer in this region back in 1995 and we only came into healthcare in 2008. We have a strong R& D team, work closely with distributors to develop products with unique properties such as the elimination of skin allergies, lower chemical content to meet the food industry requirements and even a new type of environmentally friendly biodegradable gloves. 3. While we know that COVID-19 has caused a global supply shortage of gloves, would you be able to share more details on the economics behind the demand and supply of gloves going into 2022?Mr. Wong: Based on the information from Malaysian Rubber Glove Manufacturers Association (MARGMA), consumption of healthcare gloves stands at about 330 billion gloves per annum and growing 8 &ndash 10% annually (equivalent to around 30 &ndash 33 billion gloves). In addition, there are also more industries that require gloves such as the service industry. Thus, we are quite optimistic that even after the COVID-19 pandemic, the demand for gloves would still be very strong. 4. Drilling down into the numbers &ndash we see that Riverstone has delivered an incredible Q2 FY2020 with net profits and positive cash flow up 279% and 764% compared to the previous year. Can we expect an even better year-on-year growth in the next few quarters to come?Mr. Wong: I would like to share on the chronological price change recently. Due to COVID-19 and shortage of gloves in the market, we have increased our selling price by 10% in May and also 10% in June and July. We are not stopping there because there is an imbalance of demand and supply. There are more spot buyers coming in and even our existing customers are asking for higher volume. Hence, investors can expect that Riverstone&rsquo s revenue and profit margins will grow year-on-year even though we are at full production capacity. 5. As seen from your corporate presentation, dividends per share has steadily grown in the past years since year 2006. Can investors look forward to a bumper/special dividend this year due to the company&rsquo s positive developments? Or is the management team looking more towards inorganic growth?Mr. Wong: Historically, Riverstone has maintained a 40% dividend pay-out ratio. Taking into account the strong growth this year, we will set aside S$100 million cashflow for capacity expansion and then work out the dividend pay-out based on the balance. 
|
||||
| Useful To Me Not Useful To Me | |||||
|
highlander
Senior |
06-Dec-2020 23:46
|
||||
|
x 1
x 0 Alert Admin |
My personal opinion on why Riverstone' s glove business model is strong and sustainable : 1. With other glove companies concentrating on producing more healthcare glove, Riverstone is expanding their capacity for BOTH cleanroom and healthcare glove.
2. Any new glove players are unlikely to venture into cleanroom gloves production in view of the high entry barrier. a) Customers in the semiconductor and high-tech industries have a totally different set of stringent requirement. Besides testing the gloves, they will need to audit the factory before approving them. This typically takes at least 6 months.
b) You need to have a very complete set-up to do all the cleanroom parameters testing. Just go to Riverstone websites to see the state-of-art analytical lab equipment they have. ( https://www.riverstone.com.my/quality.html ) 3. With tight supply and minimum competition, the ASP of cleanroom gloves will likely to continue to trend upward in the next few quarters.
|
||||
| Useful To Me Not Useful To Me | |||||
|
highlander
Senior |
06-Dec-2020 22:30
|
||||
|
x 0
x 0 Alert Admin |
With the news on EPF buying more Riverstone shares last week, I also believe it is due to the strong contribution from Cleanroom glove and that it is sustainable.
In relation to this, I re-post the sharing by bro Weiwulah on Riverstone .. worth taking a few minutes to hear the view of the analyst.
https://youtu.be/xXYoR8d794Q
|
||||
| Useful To Me Not Useful To Me | |||||
|
wavehunter
Supreme |
06-Dec-2020 17:25
Yells: "Trade what you see, not what you hope to see." |
||||
|
x 0
x 0 Alert Admin |
" Which Corp boss dare to be dishonest to EPF ?" 1MDB.  Juz kidding. 
|
||||
| Useful To Me Not Useful To Me | |||||
|
Peter88
Senior |
06-Dec-2020 15:46
|
||||
|
x 0
x 0 Alert Admin |
Which Corp boss dare to be dishonest to EPF ? Who own EPF ? For TG , it was an unexpected disaster that can happen to any company if they are complacent . EPF should have some insider nfo that the problems of TG is more serious than what man in the street know . Believeother glove makers are learning the lesson from TG and ill not follow its footstep .
|
||||
| Useful To Me Not Useful To Me | |||||
|
zandlery
Supreme |
06-Dec-2020 14:51
|
||||
|
x 0
x 0 Alert Admin |
Yes. Jus implying if anything sinister going on with the company, I believe the EPF during due diligence should be able to detect before having stake in the company.
Government shld have access to more resources than those shortist. And something to note, could have higher chance they will add somemore since they divest quite an amount from top glove. Gotta re-adjust their portfolio.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Superfast
Supreme |
06-Dec-2020 11:34
|
||||
|
x 0
x 0 Alert Admin |
Tq boss...
|
||||
| Useful To Me Not Useful To Me | |||||